Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood (2024) 144 (3): 262–271.

https://doi.org/10.1182/blood.2024023944

Published: 2024

Includes: Supplemental data

Journal Articles

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Blood (2023) 142 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2023-173815

Published: 2023

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clementine Sarkozy, Mary Callanan, Catherine Thieblemont, Lucie Oberic, Barbara Burroni, Krimo Bouabdallah, Gandhi Laurent Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Houot, Franck Morschhauser, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Olivier Hermine, Elizabeth A. Macintyre, Steven Le Gouill

Blood (2023) 142 (Supplement 1): 980.

https://doi.org/10.1182/blood-2023-174416

Published: 2023

Journal Articles

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Blood (2023) 142 (Supplement 1): 299.

https://doi.org/10.1182/blood-2023-173615

Published: 2023

Journal Articles

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Blood (2022) 140 (Supplement 1): 2310–2312.

https://doi.org/10.1182/blood-2022-156789

Published: 2022

Journal Articles

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Blood (2022) 140 (Supplement 1): 3680–3682.

https://doi.org/10.1182/blood-2022-170841

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adults with Primary Mediastinal B Cells Lymphoma (PMBCL): A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) Group

Blood (2021) 138 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2021-146857

Published: 2021

Journal Articles

Radiotherapy (WBRT) or Autologous Stem-Cell Transplantation (ASCT) for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Long-Term Results of the Intergroup Anocef-Goelams Randomized Phase II Precis Study

Blood (2021) 138 (Supplement 1): 658.

https://doi.org/10.1182/blood-2021-146389

Published: 2021

Journal Articles

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood (2021) 137 (17): 2307–2320.

https://doi.org/10.1182/blood.2020008750

Published: 2021

Includes: Supplemental data

Journal Articles

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Mary B. Callanan, PhD, Elizabeth Macintyre, PhD MD, Marie-Helene Delfau-Larue, MD PhD, Catherine Thieblemont, MD PhD, Lucie Oberic, MD, Emmanuel Gyan, MD PhD, Krimo Bouabdallah, MD, Rémy Gressin, MD, Gandhi Damaj, MD PhD, Olivier Casasnovas, MD, Vincent Ribrag, MD, Samuel Griolet, Bénédicte Burlet, Benjamin Tournier, PhD, Sylviane Ragot, M.Sc, Caroline Bodet-Milin, Olivier Hermine, Steven Le Gouill, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140457

Published: 2020

Journal Articles

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

Louise Bouard, MDin training, Catherine Thieblemont, Krimo Bouabdallah, MD, Thomas Gastinne, MD, Anne Moreau, MD, Sibylle Masse, Rémy Gressin, MD, Lucie Oberic, MD, Alexis Caulier, MD, Emmanuel Gyan, MD PhD, Victoria Cacheux, Olivier Casasnovas, Olivier Hermine, Steven Le Gouill, MD PhD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-139990

Published: 2020

Journal Articles

P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials

Barbara Burroni, Anne Moreau, MD, Mathieu Baldacini, MD, Antoine Martin, MD PhD, Steven Le Gouill, Vincent Ribrag, Rémy Gressin, MD, Chantal Brochet, Martin H. Dreyling, MD PhD, Samuel Griolet, Yannick Le Bris, PharmD, Morgane Cheminant, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Luc Mathieu Fornecker, MD PhD, Alexandra Traverse-Glehen, MD PhD, Danielle Canioni, MD

Blood (2019) 134 (Supplement_1): 2820.

https://doi.org/10.1182/blood-2019-129790

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Blood (2019) 134 (Supplement_1): 2618.

https://doi.org/10.1182/blood-2019-130642

Published: 2019

Journal Articles

Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation

Arnaud Jaccard, MD PhD, Sammara Chaubard, MD, Jean-François Benoist, MD, Lucile Couronne, Laure Philippe, MD, Emmanuel Gyan, MD PhD, Ronan Le Calloch, MD, Aline Moignet Autrel, MD, Rémy Gressin, MD, Jacques Vargaftig, MD PhD, Aline Clavert, MD, Emmanuel Bachy, MD PhD, Olivier Hermine, MD PhD

Blood (2018) 132 (Supplement 1): 5351.

https://doi.org/10.1182/blood-2018-99-118439

Published: 2018

Journal Articles

Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study

Blood (2018) 132 (Supplement 1): 999.

https://doi.org/10.1182/blood-2018-99-110354

Published: 2018

Journal Articles

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

Blood (2018) 131 (2): 174–181.

https://doi.org/10.1182/blood-2017-07-793984

Published: 2018

Includes: Supplemental data

Journal Articles

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

David Sibon, MD PhD, Dinh-Phong Nguyen, MD, Norbert Schmitz, MD, Ritsuro Suzuki, MD PhD, Andrew L Feldman, MD, Remy Gressin, MD, Laurence Lamant, MD PhD, Dennis D. Weisenburger, MD, Shigeo Nakamura, MD PhD, Marita Ziepert, PhD, Matthew J Maurer, MS, Martin Bast, James O. Armitage, MD, Julie M. Vose, MDMBA, Herve Tilly, Jean-Philippe Jais, MD PhD, Kerry J Savage, MD

Blood (2017) 130 (Supplement 1): 1514.

https://doi.org/10.1182/blood.V130.Suppl_1.1514.1514

Published: 2017

Journal Articles

Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

Blood (2017) 130 (Supplement 1): 190.

https://doi.org/10.1182/blood.V130.Suppl_1.190.190

Published: 2017

Journal Articles

B-Cell Prolymphocytic Leukemia, a Rare Lymphoproliferative Disorder: Analysis of 35 Cases, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Caroline Algrin, Elise Chapiro, Justine Saviellis, Anne Quinquenel, Anne-Sophie Michallet, MD PhD, David Ghez, MD PhD, Pierre Feugier, MD, Annie Brion, Cecile Tomowiak, MD, Luc-Matthieu Fornecker, Remy Gressin, MD, Laurent Sutton, MD, Karim Maloum, Catherine Settegrana, Lucile Baseggio, MD, Quentin Vincent, Florence Nguyen-Khac, MD PhD, Véronique Leblond

Blood (2017) 130 (Supplement 1): 4310.

https://doi.org/10.1182/blood.V130.Suppl_1.4310.4310

Published: 2017

NARROW

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study

Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Adults with Primary Mediastinal B Cells Lymphoma (PMBCL): A Retrospective Study on Behalf of the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC) and the Lymphoma Study Association (LYSA) Group

Radiotherapy (WBRT) or Autologous Stem-Cell Transplantation (ASCT) for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Long-Term Results of the Intergroup Anocef-Goelams Randomized Phase II Precis Study

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial

P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials

Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study

Monitoring Asparaginase Activity in 21 Patients with Extranodal NK/T-Cell Lymphoma Shows a Very High Proportion of Asparaginase Inactivation

Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma

Systemic ALK-Positive Anaplastic Large-Cell Lymphoma (ALCL): Final Analysis of an International, Individual Patient Data Study of 263 Adults

Obinutuzumab Versus Rituximab in Combination with ACVBP-14 or CHOP-14 Following a PET-Driven Strategy in Aa-IPI 1-3 DLBCL Patients (< 60 years): Third Planned Interim and Final Analyses of the Gained Trial

B-Cell Prolymphocytic Leukemia, a Rare Lymphoproliferative Disorder: Analysis of 35 Cases, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only